• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Environmental Research and Public Health >Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective
【2h】

Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective

机译：从塞浦路斯NHS付款人的角度比较在HER2阳性早期乳腺癌中使用一年曲妥珠单抗辅助治疗的三种治疗方案的现实情况下的成本-效果分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: This study is one of the first real-world cost-effectiveness analyses of one-year adjuvant trastuzumab used in HER2-positive early female breast cancer in comparison to chemotherapy alone. It is just the second one in Europe, the first one in Cyprus, and the fourth one worldwide ever carried out using real-world data. Methods: Using a Markov model (four health states), a cost-effectiveness analysis was carried out both over 20 years and for a lifetime horizon. The sampling method used in this study was the randomized sampling of 900 women. Results: The findings for the 20-year horizon showed that all trastuzumab arms were more cost-effective, with a willingness-to-pay threshold of only €60,000 per quality-adjusted life year (QALY) [incremental cost-effectiveness ratios (ICER): €40,436.10/QALY]. For the lifetime horizon, with thresholds of €20,000, €40,000, and €60,000/QALY, all trastuzumab arms were found to be more cost-effective (ICER: €17,753.85/QALY). Moreover, for the 20-year and the lifetime horizons, with thresholds of €20,000/QALY, €40,000/QALY, and €60,000/QALY, the most cost-effective of the three subgroups (anthracyclines and then trastuzumab, no anthracyclines and then trastuzumab, and anthracyclines, taxanes, and trastuzumab) was that of anthracyclines and then trastuzumab (ICER: €18,301.55/QALY and €8954.97/QALY, respectively). Conclusions: The study revealed that adjuvant trastuzumab for one year in female HER2-positive early breast cancer can be considered cost-effective.
机译：简介：这项研究是与单纯化疗相比，HER2阳性早期女性乳腺癌中使用的一年期曲妥珠单抗辅助治疗的第一个现实成本分析之一。它仅是欧洲的第二位，塞浦路斯的第一位，也是全世界使用实际数据进行的第四次。方法：使用马尔可夫模型（四个健康状态），进行了20多年以及整个生命周期的成本效益分析。本研究使用的抽样方法是对900名女性进行随机抽样。结果：20年的研究结果显示，所有曲妥珠单抗组均具有更高的成本效益，每个质量调整生命年（QALY）的支付意愿门槛仅为60,000欧元[成本效益比增量（ICER） ）：€40,436.10 / QALY]。对于整个生命周期，阈值分别为20,000欧元，40,000欧元和60,000欧元/ QALY，发现所有曲妥珠单抗均更具成本效益（ICER：17,753.85欧元/ QALY）。此外，对于20年和一生的生命周期，阈值分别为20,000欧元/每QALY，40,000欧元/每QALY和60,000欧元/每QALY，这三个子组（蒽环类药物然后是曲妥珠单抗，无蒽环类药物然后是曲妥珠单抗，蒽环类，紫杉烷类和曲妥珠单抗）分别是蒽环类和曲妥珠单抗（ICER：分别为18,301.55欧元/ QALY和8954.97欧元/ QALY）。结论：研究表明曲妥珠单抗辅助治疗女性HER2阳性的早期乳腺癌可以被认为具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号